Zoetis Inc.

Zoetis Inc., doing business as Zoetis, operates as a for-profit animal health company supplying veterinary pharmaceuticals, vaccines, diagnostic equipment, and laboratory instruments to federal agencies as a prime contractor on a full-and-open basis, with no SBA set-aside designations across its portfolio. Headquartered in Parsippany, New Jersey, Zoetis holds a named subsidiary, Abaxis, Inc., a manufacturer of diagnostic instruments, and operates primarily under NAICS codes spanning pharmaceutical preparation manufacturing, in-vitro diagnostic substance manufacturing, and biological product manufacturing, with work classified under PSC codes for veterinary drugs and biologicals, diagnostic substances, and laboratory equipment.

Zoetis's federal footprint centers on specialized animal health products. Representative prime work includes a $5.045 million single-award Indefinite Delivery Contract (IDC) with the USDA Animal and Plant Health Inspection Service (APHIS) Veterinary Services running through May 2030 for Mycobacterium bovis purified protein derivative (PPD) tuberculin in multiple vial sizes, which has generated seven delivery orders totaling $3.3 million; a $626,850 delivery order (May 2026) from USDA APHIS Veterinary Services for PPD tuberculin under that base IDC; a $999,963.92 purchase order (May 2024) from USDA APHIS Veterinary Services for Zoetis FLU DETECT Avian Influenza Virus Type A Antigen Test Kits; a $1.346 million definitive contract (April 2022) with USDA APHIS Veterinary Services for Classical Swine Fever Virus vaccine, valued at $1.346 million with disposal services through August 2028; and a $99,680 purchase order (April 2026) from USDA APHIS for BM86 Immunomodulator cattle fever tick vaccine under the Cattle Fever Tick Eradication Program, awarded as a sole-source acquisition under FAR Part 12 for commercial items due to Zoetis's exclusive rights to the product.

Customer concentration is acute. The Department of Agriculture's APHIS Veterinary Services accounts for 33 awards and $74.2 million of combined potential value (73% of total portfolio), with an additional $20.3 million in potential value split across two other USDA APHIS line organizations, giving USDA agencies roughly $94.5 million of the $102.1 million combined portfolio value. The Department of Health and Human Services Indian Health Service contributes 17 awards for rabies vaccines and associated supplies worth $393 thousand combined potential value. The Defense Logistics Agency Troop Support Medical, the National Institutes of Health, and the Department of State Bureau of South and Central Asian Affairs each place smaller order volumes. Zoetis serves 19 distinct customer agencies but is substantially dependent on USDA APHIS as a single customer; the top five customers by award count account for 74% of awards.

Zoetis places work under five named USDA APHIS Indefinite Delivery Contracts. IDC 12639520D0026 carries seven task orders totaling $3.3 million potential value; IDC AG6395C150051 carries seven task orders totaling $3.2 million; IDC 12639525D0024 carries two task orders totaling $1.1 million; IDC AG6395C140106 carries two task orders totaling $497 thousand; and IDC AG6395C140110 carries one task order valued at $2.8 million. Additional work flows through single-source and full-and-open purchase orders to federal agencies including the Indian Health Service, Department of State, Department of the Army Training and Doctrine Command, Department of Defense Research Development and Engineering Command, Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, Fish and Wildlife Service, and Bureau of African Affairs.

Activity has been episodic over the past five years: nine awards in 2022, seven in 2023, thirteen in 2024, five in 2025, and six in 2026 as of September. Over the full snapshot, the vendor has recorded 99 prime awards across 19 agencies with $102.1 million in combined potential value and $25.7 million obligated (25% draw-down rate). Zoetis operates exclusively as a prime contractor with no subcontract footprint in the source data. Recompete exposure in the next twenty-four months is modest: five awards with completion dates between October 2026 and October 2028 carry combined potential value of $2.2 million, concentrated in small diagnostic equipment and rabies vaccine orders from IHS and low-value medical supply transactions, with the substantial USDA APHIS base IDC extending through May 2030.